Pediatrics, Pediatric Hematology-Oncology · Orange, CA
NPI
1992900641
Since 2007
Specialty
Pediatrics, Pediatric Hematology-Oncology
Code 2080P0207X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
701 South Parker Street, Suite 1000
Orange, CA, 92868
Phone (714) 221-1200
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$869K
129 prescriptions
Company payments, 2025
$3,312
From 11 companies
Medicare prescription drug claims, 2024
In 2024, the drug Esteban I Gomez prescribed most often to Medicare patients was Deferasirox, with 52 prescriptions and refills. In total Esteban I Gomez wrote 129 Medicare prescriptions that cost $869K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-08-01.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Deferasirox Generic | 52 | 52 | Under 11 | $124K |
| Xarelto Rivaroxaban | 17 | 45 | Under 11 | $25K |
| Tavalisse Fostamatinib Disodium | 12 | 12 | Under 11 | $180K |
Brand drugs: 62 claims; generic drugs: 67 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Esteban I Gomez $3,312 ($3,312 in general payments such as food, travel and fees) from 11 companies. The largest payer was CSL Behring with $2,697.
| Company | Payments | Amount |
|---|---|---|
| CSL Behring CSL.AX | 1 | $2,697 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $175 |
| Genzyme Corporation SNY | 6 | $159 |
| Novo Nordisk Inc NVO | 2 | $62.73 |
| BioMarin Pharmaceutical Inc. BMRN | 2 | $60.5 |
| Genentech, Inc. ROG.SW | 1 | $44.7 |
| Agios Pharmaceuticals, Inc. AGIO | 1 | $32.39 |
| Boston Scientific Corporation BSX | 1 | $27.81 |
| Genentech USA, Inc. ROG.SW | 1 | $21.16 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $17.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.